Objectives: At the end of this program, participants should be able to:

1. Review the biologic rationale, related to the role of RhoKinase (ROCK) ignaling in CA pathogenesis and the use of atorvastatin as a ROCK inhibitor.

2. Expalin QSM and DCEQP imaging as biomarkers of CA iron deposit and vascular leak, linked to clinical activity.

3. Describe the approved Phase I-IIa proof of concept clinical trial, with emphasis on design innovations, and go-no go implications.

Session date: 
07/11/2018 - 8:30am to 9:30am CDT
UCMC J-320
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Sean Polster, MD